- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact
Romanian Academy
The Publishing House of the Romanian Academy
ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.
-
General Endocrinology
Mohammadi M, Hedayati M, Zarghami N, Ghaemmaghami S
Resistin Effect on Telomerase Gene expression in Gastric Cancer Cell Line AGSActa Endo (Buc) 2016 12(2): 145-149 doi: 10.4183/aeb.2016.145
AbstractBackground. Resistin, as an adipokine, has been shown to be increased in serum plasma of gastric cancer patients and suggested to be a major factor in gastric carcinogenesis. However, it is still not clear how Resistin influences gastric cancer progression. The aim of this study was to evaluate Resistin effect on cell proliferation and expression of telomerase gene in gastric cancer cell line (AGS). Methods. In this study, the proliferating activity of AGS cells stimulated with Resistin was also evaluated by using 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2HTetrazolium- 5-Carboxanilide (XTT) assay and trypan blue staining method. To investigate telomerase gene expression affected by Resistin, total RNA was extracted, cDNA was synthesized and expression of hTERT mRNA was carried out by real-time reverse transcription polymerase chain reaction. Results. Exogenous Resistin has induced gastric cancer cells proliferation in a dose-dependent manner and could improve cell viability. Also the expression of Human Telomerase Reverse Transcriptase (hTERT) was upregulated in 24 hours, after Resistin treatment. Conclusions. This study has shown Resistin induces exogenously gastric cancer cell proliferation and increases hTERT gene expression. These findings may clarify the role of Resistin in gastric carcinogenesis. Therefore blocking Resistin signaling and limiting its secretion may be valuable for the treatment of gastric cancer. -
General Endocrinology
Rosianu A, Lazar E, Raica M
Oncoprotein c-erb B2 - prognostic significance in invasive breast cancerActa Endo (Buc) 2005 1(2): 145-156 doi: 10.4183/aeb.2005.145
Abstract ReferencesObjective: The invasive mammary cancer is the most frequent malignant tumor of a woman. Among the potential prognostic factors are included the biomarkers which measure or are associated with biological processes involved in the tumoral progression.We studied the prognostic importance of the oncoprotein c-erbB2 in the invasive mammary cancer.\r\nMaterials and methods: We included in the study 56 female patients suffering from invasive mammary cancer.The tissue fragments were fitted in formol, included to paraffin, commonly stained with hematoxylin-eosine (HE); for the determination of the c-erbB2 we\r\nused the immunohistochemical method of the avidin-biotin (ABC) complex.\r\nResults: From the total of 56 tumors, 38 (67.9%) presented different degrees of positivity; 18 (32.1%) did not express the oncoprotein c-erbB2.\r\nConclusions: The positivity of oncoprotein c-erbB2 was correlated with the size of the tumor; the carcinomas which are not infiltrative ductal, known as having a better prognostic, were c-erbB2 negative.1. Hartmann Lynn, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE and Roche PC. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Cancer 1994; 74(11): 2956-2962.2. Guerin M, Gabillot M, Mathieu MC et al. Structure and expression of c-erbB2 and EGFR receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int. J. Cancer 1989; 43: 201. [CrossRef]3. Gullik JW, Lowe SB, Wright C et al. c-erbB2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved nodes. Br. J. Cancer 1991; 63: 434-438. [CrossRef]4. Gusterson BA, Golber RD, Goldhirsch A, Prince KN, love Soderbergh J, Anboyhagen Ret. et al. Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.5. Paul P, Rosen MD, Martin L, Lesser Ph D, Crispinita D, Arrayo CLS et al.: Immunohistochemical detection of HER2/neu in patients with axillary lymph nodes negative breast carcinoma. Cancer 1995; 75(6):1320-1325. [CrossRef]6. Seshardi R, Firgaira FA, Horsfall DJ, Mc Caul K, Setur V, Vithen P. Clinical significance of HER2/neu oncogene amplificator in primary breast cancer. J. Clin. Oncol. 1993;11:1936-1946.7. Toikkanen S, Kujari H. Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long term follow-up. Hum. Pathol. 1989;20:758-764. [CrossRef]8. Garcia I, Dietrich P, Aapro M, Vauthier G, Vadus L, and Engel E. Genetic alteration of c-myc, c-erbB2 and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res. 1989; 49:6675.9. Parkes HC, Lillycrop K, Howell A and Craig RK. c-erbB2 mRNA expression in human breast tumors: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br. J. Cancer 1990;61: 39. [CrossRef]10. Perren TJ. c-erbB2 oncogene as a prognostic marker in breast cancer. Br. J. Cancer 1991; 63: 328- 332. [CrossRef]11. Silverberg G. Steven. Principles and practice of surgical pathology, vol I, 1983: 245, 266-267, 270- 295.12. Rosen PP, Martin L, Crispinita L, Arrayo D, Cranor M, Borgen P, Norton L. p53 in node negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features and prognosis. HJ. Clin Oncol. 1995; 13(4): 821-830.13. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707. [CrossRef]14. Van de Vivjer MJ, Peterse JL, Moori WJ, Wisman P, Lomans J, Dalesio O et al: HER2/neu protein overexpression in breast cancer: association with comedothipe ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med.15. Wright C, Angus B, Nicholson S et al: Expression of c-erbB2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989; 49: 2087-2090.16. Lovekin C, Ellis JO, Lockr A et al. c-erbB2 oncoprotein expression in primary and advanced breast cancer. Br. J. Cancer 1991; 63:439. [CrossRef]17. Borg A, Tandon AK, Sigurdsson H et al. HER2/neu amplificattion predicts poor survival in nodepositive breast cancer. Cancer Res. 1990; 50:4332.18. Gasparini G, Dal Fior S, Pozza P, Bevilaqua P. Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. Breast Cancer Res. Treat. 1989; 14: 329-336. [CrossRef]19. Barnes DM, Lammine GA, Mollis RR, Gullik WL, Allen DS and Altman DG. An immunohistochemical evaluation of c-erbB2 expression in human breast carcinoma. Br. J. Cancer 1988; 58; 448. [CrossRef]20. Ro YJ, El Naggar A, Ro J et al. c-erbB2 amplification in node negative human breast cancer. Cancer Res. 1989; 49: 6941.21. May E, Mouriesse M, May-Levin F, Contesso G, and Delarue JC. A new approach allowing an early prognosis in breast cancer; a ratio of estrogen receptor (ER) ligand binding activity to the ERspecific mRNA level. Oncogene 1989; 4:1037.22. Adnane J, Guadray P, Simon MP, Simony-Lafontaine J, Jeanteur p and Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989; 4: 1389.23. Tetu B., Brisson J. Prognostic significance of HER2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359. [CrossRef]24. Ravdin PM., Chamness GC.The c-erbB2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecule markers. Gene (in press).25. Fattaneh A, Tavassoli PD. Pathology and genetics of tumors of the breast and female genital organs. IARCPress, Lyon, 2003: 13-15. -
Book Review
Niculescu DA
Nutrition and the Cancer PatientActa Endo (Buc) 2011 7(1): 147-147 doi: 10.4183/aeb.2011.147
-
General Endocrinology
Méndez-López LF, Zavala-Pompa A, Fuentes-Vera MA, Pacheco-Calleros J, Escobar-Moreno AC, Cortés-Gutiérrez EI, Dávila-Rodríguez MI
Quantification of Leptin Receptor Expression in Endometrial Tissue Throughout the Human Menstrual CycleActa Endo (Buc) 2015 11(2): 147-154 doi: 10.4183/aeb.2015.147
AbstractLeptin is much more than a simple sensor of body fat levels. Its biological activities, include angiogenesis, osteogenesis and modulation of the immune and reproductive systems. There are no reports on fluctuations of the level in normal human functional glandular epithelium during the menstrual cycle. Objective. We aimed to determine the expression level of the leptin receptor by immunohistochemistry and to correlate this with estrogen and progesterone receptor levels in normal endometrial tissue throughout the menstrual cycle. Study design. Thirty-seven paraffin wax blocks of biopsy specimens of histologically normal endometrium were evaluated and classified according to the stage of the menstrual cycle during the 2004–2006 period. Results. The OB-R level underwent fluctuations during the menstrual cycle in the different tissue compartments; these were most marked in the functional glandular epithelium and during the proliferative stage. OB-R levels were correlated positively with the expression levels of estrogen and negatively with those for progesterone receptors, suggesting that these steroids modulate the expression of OB-R in vivo. Conclusion. This finding underscores the importance of considering the menstrual cycle stage for studies seeking possible impacts of the OB-R on reproductive pathology, because its expression level varies with the hormonal environment. -
Book Review
Badiu C
Environmental Contaminants and Endocrine HealthActa Endo (Buc) 2023 19(1): 147-148 doi: 10.4183/aeb.2023.147
Abstract- -
Book Review
Badiu C
Polyendocrine Disorders and Endocrine Neoplastic SyndromesActa Endo (Buc) 2021 17(1): 147-148 doi: 10.4183/aeb.2021.147
Abstract- -
General Endocrinology
Kwinta B, Myszka A, Krzyzewski RM, Klis KM, Dragan MR, Adamek D
Assessment and Comparison of Hormonal Immunoexpression and the Clinical Picture in Patients with Pituitary AdenomasActa Endo (Buc) 2020 16(2): 148-155 doi: 10.4183/aeb.2020.148
AbstractIntroduction. Symptoms related to hypersecretion of hormones in patients with pituitary adenomas do not always correlate with immunohistochemical staining results. Objective. To evaluate the relationship between the pituitary adenomas hormone immunoexpressions and endocrine presentations. Patients and methods. The clinical status and immunoexpression of 72 patients who underwent transsphenoidal surgery for pituitary adenomas were analyzed. Results. Macroadenomas were diagnosed in 51 cases (70.84%), while microadenomas were found in 21 cases (29.16%). The 72 adenoma specimens were divided into 22 monohormonal, 21 plurihormonal, 21 immunonegative and 8 unreliable specimens. The positive immunohistochemical staining results occurred as follows: prolactin and growth hormone 25% each, adrenocorticotropic hormone 13.89%, thyroid-stimulating hormone 5.56%, leuteinizing hormone and follicle-stimulating hormone 12.5%, glycoprotein hormone alpha-subunit 22.22%. Statistically significant relationships between the immunohistochemical presentation and the preoperative diagnosis were found for prolactin and hyperprolactinemia, growth hormone and acromegaly and adrenocorticotropic hormone and Cushing’s syndrome. Conclusions. The lack of full concordance between the clinical presentations and immunohistochemical staining was mainly a result of the presence of nonfunctioning adenomas, plurihormonal adenomas and unreliable specimens. The morphometric method introduced in this study, utilizing the immunoexpression index, provided a very precise evaluation of pituitary adenomas pathology. -
Perspectives
Hritcu LD, Borcea D, Anton E, Morosan S, Pasca S, Trinca C, Spataru MC, Petrariu FD, Burtan LC, Ciobica A, Curpan A , Timofte D
Experimental Induction of Type 2 Diabetes Mellitus and the Efficiency of Bariatric Surgery in its Reversal in RatsActa Endo (Buc) 2021 17(2): 149-156 doi: 10.4183/aeb.2021.149
AbstractBackground. Following recent years, there is an increased body of literature on the connections that might exist between type 2 diabetes mellitus and the efficiency of bariatric surgery in its reversal compared to other medical approaches such as dieting. Aim. To induce experimentally type 2 diabetes mellitus in rats in order to observe the effects of bariatric surgery in the recovery as well as the reestablishment of normal insulin levels in order to extend the findings in house animals. Materials and methods. This study was conducted in three stages: the first consisted in inducing type 2 diabetes mellitus (T2DM) in 40 young Wistar male rats, by initially feeding them human food high in vegetal fats, oleaginous seeds, simple and complex carbohydrates, sugars, lipids, fats, proteins and fructose for a period of 8 weeks followed by a single low dose of streptozotocin (STZ), administered through intraperitoneal injection. The second stage of the study started when the rats became obese and therefore qualified for the bariatric procedure and the third stage consisted of post-operation supervision and care. The surgical procedure, performed on 10 obese rats, consisted in reducing the size of the stomach by partial gastrectomy of a 1.5 – 2.0 cm wide and 6.5 – 7.5 cm long area on the large curvature. Results. Showed rapid improvements in body weight and blood sugar control after 9 days. Conclusion. After putting the rats on a diet high in carbohydrates, sugars, lipids and fats and administering them STZ, the induction of type 2 diabetes was successful and the partial gastrectomy led to a better blood sugar control. The bariatric procedure provides a faster therapeutic response than conventional diets. -
Perspectives
Yue RH, Hui B, Chen H
Effect of the C-Terminus of TSHR on T4 and Trab Expression In BALB/C MiceActa Endo (Buc) 2023 19(2): 149-154 doi: 10.4183/aeb.2023.149
AbstractContext. The expression of TSHR-C on the serum tetraiodothyronine (T4) and TSH receptor antibody (TRAb) levels are rarely studied. Objective. The effect of TSHR-c on T4 and TRAb levels and concomitant thyroid histological changes in mice was investigated. Design. Animal experimental study. Subjects and methods. Female BALB/c mice at 6-8 weeks of age were immunized with the thyroid stimulating hormone receptor antigen C-terminus (TSHR-C), and randomly divided into control group (treated with the corresponding concentrations of normal saline) and four experimental subgroups: TSHR-c1 subgroup (4 μg), TSHR-c2 subgroup (6 μg), TSHR-c3 subgroup (8 μg) and TSHR-c4 subgroup (10 μg). Serum T4 and TRAb levels were determined. Results. The serum T4 level decreased significantly in the experimental mice as the concentration increased. All the experimental mice were positive for serum TRAb (experimental groups: 40 positive/40, 100% vs. control group: 3 positive/10, 30%) compared to the control group (P =0.000). HE staining showed that the follicles in the control mice were composed of small to medium-sized round follicles, whereas the follicles in the experimental mice were irregularly enlarged under light microscope. Conclusions. TSHR-c immunization resulted in thyroid hormone changes like those observed in hypothyroidism, probably due to the induction of TRAb generation. -
Book Review
Bowker L , James D. Price, Smith S
Oxford Handbook of Geriatric MedicineActa Endo (Buc) 2013 9(1): 149-149 doi: 10.4183/aeb.2013.149
Abstract-